To the full analysis
Orchestra BioMed Holdings stock: growth
OBIOOrchestra BioMed Holdings reported $33.48M in revenue for fiscal 2025, up 1,169.2% on the prior year, up 42.5% a year on average over up to five years.
Daily figure as of 13 Nov 2026
Revenue (Annual rate)
42.5%
per year from 2020 to 2025, per share 20.3%
Earnings (Annual rate)
no data
Free cash flow (Annual rate)
no data
Growth per year by period
What reaches shareholders is growth per share: buybacks lift it, new shares dilute it.
| since 2020 | |
|---|---|
| Revenue | 42.5% |
| Revenue per share | 20.3% |
| Earnings | no data |
| Earnings per share | no data |
| Free cash flow | no data |
| Free cash flow per share | no data |
Fiscal years at a glance
How revenue and earnings grow
- Revenue
- Earnings
- Free cash flow
Figures as a table
| Year | Revenue | Earnings | Free cash flow |
|---|---|---|---|
| 2020 | $5.7M | −$21.36M | −$26.72M |
| 2021 | −$782K | −$23.01M | −$19.7M |
| 2022 | $3.53M | −$33.61M | −$29.88M |
| 2023 | $2.76M | −$49.12M | −$46.21M |
| 2024 | $2.64M | −$61.02M | −$50.85M |
| 2025 | $33.48M | −$52.7M | −$49.45M |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Neutral since 13 Nov 2026, previously Weak
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.